Dr. Noonberg was appointed to our board of directors May 2023.
Dr. Noonberg is a physician-scientist with a diverse background in translational science, clinical development, medical affairs, and corporate governance. She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization. Dr. Noonberg currently serves as the Chief Medical Officer of Metagenomi, a privately held genomics company, where she is advancing its gene editing technology platform toward the clinic. She previously served as Chief Medical Officer of Maze Therapeutics, Nohla Therapeutics and Prothena Biosciences and prior to that, held clinical development executive leadership roles at BioMarin and at Medivation. Her industry experience is complemented by more than 10 years of experience treating patients as a hospitalist physician.
Dr. Noonberg currently serves on the Board of Directors at Neurogene and previously served on the Board of Directors at Protagonist Therapeutics and Neoleukin Therapeutics. She trained in internal medicine at Johns Hopkins Hospital, received an M.D. from the University of California, San Francisco, a Ph.D. in bioengineering from the University of California, Berkeley, and a bachelor’s degree in engineering science from Dartmouth College.